Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ: WVE )

13.48 +0.07 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
Via Investor's Business Daily
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
What Analysts Are Saying About WAVE Life Sciences Stock
Via Benzinga
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
What's Next: WAVE Life Sciences's Earnings Preview
Via Benzinga
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
This stock currently has a good balance of risk and potential rewards. 
Via The Motley Fool
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Gains Over 1%; BioVie Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
Via Benzinga
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
Via Benzinga
Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With Wave Life Sciences Stock On Tuesday?
Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington's disease, demonstrates promise as a disease-modifying therapy. 
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023
WVE stock results show that WAVE Life Sciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback